Abstract
Type III Secretion Systems (T3SSs) are highly organized multi-protein nanomachines which translocate effector proteins from the bacterial cytosol directly into host cells. These systems are required for the pathogenesis of a wide array of Gram-negative bacterial pathogens, and thus have attracted attention as potential antibacterial drug targets. A decade of research has enabled the identification of natural products, conventional small molecule drug-like structures, and proteins that inhibit T3SSs. The mechanism(s) of action and molecular target(s) of the majority of these inhibitors remain to be determined. At the same time, structural biology methods are providing an increasingly detailed picture of the functional arrangement of the T3SS component proteins. The confluence of these two research areas may ultimately identify non-classical drug targets and facilitate the development of novel therapeutics.
Keywords: Type III secretion, virulence, Gram-negative bacteria, high-throughput screening, antibiotic drug discovery, T3SSs, Caminosides, Guadinomines, structural biology, benzanilides
Current Drug Targets
Title: The Type III Secretion System as a Source of Novel Antibacterial Drug Targets
Volume: 13 Issue: 3
Author(s): Toni Kline, Heather B. Felise, Sarah Sanowar and Samuel I. Miller
Affiliation:
Keywords: Type III secretion, virulence, Gram-negative bacteria, high-throughput screening, antibiotic drug discovery, T3SSs, Caminosides, Guadinomines, structural biology, benzanilides
Abstract: Type III Secretion Systems (T3SSs) are highly organized multi-protein nanomachines which translocate effector proteins from the bacterial cytosol directly into host cells. These systems are required for the pathogenesis of a wide array of Gram-negative bacterial pathogens, and thus have attracted attention as potential antibacterial drug targets. A decade of research has enabled the identification of natural products, conventional small molecule drug-like structures, and proteins that inhibit T3SSs. The mechanism(s) of action and molecular target(s) of the majority of these inhibitors remain to be determined. At the same time, structural biology methods are providing an increasingly detailed picture of the functional arrangement of the T3SS component proteins. The confluence of these two research areas may ultimately identify non-classical drug targets and facilitate the development of novel therapeutics.
Export Options
About this article
Cite this article as:
Kline Toni, B. Felise Heather, Sanowar Sarah and I. Miller Samuel, The Type III Secretion System as a Source of Novel Antibacterial Drug Targets, Current Drug Targets 2012; 13 (3) . https://dx.doi.org/10.2174/138945012799424642
DOI https://dx.doi.org/10.2174/138945012799424642 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of C-Type Lectins in Mycobacterial Infections
Current Drug Targets Failing a First Anti-TNF in RA: Does it Imply a Change in Target?
Current Rheumatology Reviews Role of Cytokines in the Development and Maintenance of Memory T Cells During Respiratory Viral Infection
Current Pharmaceutical Design Prediction of MicroRNA–disease Associations by Matrix Completion
Current Proteomics New Strategies in Drug Development Focusing on the Anti-Protease- Protease Balance in Alpha-1 Antitrypsin Deficiency
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Structure - Antituberculosis Activity Relationships Study in a Series of 5-(4-Aminophenyl)-4-Substituted-2,4-Dihydro-3h-1,2,4-Triazole-3-Thione Derivatives. A Combined Electronic-Topological and Neural Networks Approach
Medicinal Chemistry Anti Tumor Necrosis Factor-a Monoclonal Antibody (Infliximab) Therapy in Patients with Inflammatory Bowel Disease (IBD): Applications and Side Effects
Drug Design Reviews - Online (Discontinued) Pharmacogenomics and Personalized Medicine for the Developing World - Too Soon or Just-in-Time? A Personal View from the World Health Organization
Current Pharmacogenomics and Personalized Medicine Antimicrobial Activities of 1-H-Benzimidazole-based Molecules
Current Topics in Medicinal Chemistry Synthesis and Biological Evaluation of Curcumin-Nitroxide-Based Molecular Hybrids as Antioxidant and Anti-Proliferative Agents
Medicinal Chemistry Clinical Application of Percutaneous Puncture Biopsy Guided by Fused and 3D-reconstructed PET/CT Images
Current Medical Imaging Applications of Polymeric Nanocapsules in Field of Drug Delivery Systems
Current Drug Discovery Technologies Antimicrobial Activities of Synthetic Arylidine Nicotinic and Isonicotinic Hydrazones
Letters in Drug Design & Discovery Synthesis and Evaluation of New 5-methylisoxazole-3-carboxamide Derivatives as Antitubercular Agents
Anti-Infective Agents Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism
Current Drug Targets Surface Energy Determined by Inverse Gas Chromatography as a Tool to Investigate Particulate Interactions in Dry Powder Inhalers
Current Pharmaceutical Design Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews 1,3-Thiazolidin-4-ones: Biological Potential, History, Synthetic Development and Green Methodologies
Current Organic Synthesis Newest Strategies in the Search for Bioactive Saponins from the Tropical Plant Biodiversity
Current Drug Delivery Effect of Polarization of Ligand Charges and Estimation of MM/GBSA Binding Free Energies of Some Pyrazolo[3,4-d]pyrimidine Inhibitors of Mycobacterium Tuberculosis in View of Experimental Results
Current Enzyme Inhibition